Viewing Study NCT06394622



Ignite Creation Date: 2024-05-06 @ 8:28 PM
Last Modification Date: 2024-10-26 @ 3:28 PM
Study NCT ID: NCT06394622
Status: RECRUITING
Last Update Posted: 2024-05-01
First Post: 2024-04-28

Brief Title: A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Sponsor: Fudan University
Organization: Fudan University

Study Overview

Official Title: A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Status: RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a phase I open-label single-arm study conducted to evaluate the efficacy safety and PK of CGC729 in the treatment of advanced malignant solid tumors

Condition or diseaseadvanced malignant solid tumors InterventiontreatmentBiological CD70 CAR-NKT cells PhaseI
Detailed Description: This was a dose-expansion study we plan to enroll 6 to 12 patients with CD70-positive advanced malignant solid tumors to CGC729 treatment The intended enrollment for the evaluation of treatment efficacy and safety was planned to be 3 to 6 patients per tumor type

We used leukapheresis for cell collection The lymphodepletion procedure was conducted using a combination of fludarabine and cyclophosphamide

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None